Coya Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Coya Therapeutics, Inc. (COYA) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.90% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-11
- Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.90%, a 13.33% decline year-over-year.
- Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 4.50%, a 12.50% increase year-over-year.
- Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 4.00%, a 2.44% decline year-over-year.
- Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 4.10%.
- Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.40%, a 4.76% increase from fiscal 2024.
- Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.20%, a 5.00% increase from fiscal 2023.
- Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.00%, a 21.21% increase from fiscal 2022.
- Coya Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 3.30%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 3.90% 10-Q · filed 2026-08-11 | ||||
| 2026-03-31 | 3.90% 10-Q · filed 2026-05-12 | ||||
| 2025-12-31 | 4.40% 10-K · filed 2026-03-16 | ||||
| 2025-09-30 | 4.40% 10-Q · filed 2025-11-12 | ||||
| 2025-06-30 | 4.50% 10-Q · filed 2026-08-11 | ||||
| 2025-03-31 | 4.50% 10-Q · filed 2026-05-12 | ||||
| 2024-12-31 | 4.20% 10-K · filed 2026-03-16 | ||||
| 2024-09-30 | 4.20% 10-Q · filed 2025-11-12 | ||||
| 2024-06-30 | 4.20% 10-Q · filed 2025-08-12 | ||||
| 2024-03-31 | 4.00% 10-Q · filed 2025-05-13 | ||||
| 2023-12-31 | 4.00% 10-K · filed 2025-03-18 | ||||
| 2023-09-30 | 4.10% 10-Q · filed 2024-11-06 | ||||
| 2023-06-30 | 4.00% 10-Q · filed 2024-08-12 | ||||
| 2023-03-31 | 4.10% 10-Q · filed 2024-05-09 | 4.14% 10-Q · filed 2023-05-10 | |||
| 2022-12-31 | 3.30% 10-K · filed 2024-03-19 | ||||
| 2022-09-30 | 3.30% 10-Q · filed 2023-11-08 | ||||
| 2022-06-30 | 3.30% 10-Q · filed 2023-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |